Supplementary Table 2: Quality of life changes during cabazitaxel therapy

EORTC QLQ-C30		Baseline Mean (SD)	Post-treatment best Mean (SD)	P for change
GLOBAL HEALTH STATUS/QOL	GLOBAL HEALTH STATUS/QOL	48.80 (26.97)	71.42 (18.54)	0.015*
FUNCTION SCALES	Physical functioning	54.28 (29.42)	61.90 (32.59)	0.321
	Role functioning	76.19 (26.97)	71.43 (39.34)	0.673
	Cognitive functioning	64.28 (27.93)	80.95 (22.41)	0.216
	Social functioning	73.80 (30.21)	80.95 (27.93)	0.629
	Emotional functioning	60.71 (30.69)	80.95 (24.86)	0.170
SYMPTOM/ITEM SCALES	Fatigue	45.23 (31.49)	42.85 (35.81)	0.853
	Nausea Vomiting	28.57 (24.93)	16.66 (30.42)	0.140
	Pain	47.61	35.71	0.334

		(36.55)	(45.57)	
	Dyspnoea	9.52 (16.26)	9.52 (16.26)	1
	Insomnia	47.61(37.79)	28.57 (35.63)	0.321
	Appetite	47.61 (42.41)	28.57 (40.49)	0.231
	Constipation	71.42 (40.49)	19.0(37.79)	0.017*
	Diarrhoea	23.80(37.08)	14.28 (26.22)	0.172
	Financial difficulties	33.33 (47.14)	14.29 (37.79)	0.231

EORTC QLQ-PR25	Baseline Mean (SD)	Post-treatment best Mean (SD)	P for change
'Urinary symptoms	38.69 (19.5)	20.23 (24.58)	0.247
Bowel symptoms	14.28 (16.46)	5.95 (7.92)	0.234
Treatment related symptoms	23.01 (17.39)	7.93 (12.77)	0.170
Sex Interest	4.76 (12.59)	4.76 (12.59)	1.0

*p<0.05, significant

Abbreviations: QOL – Quality of life; EORTC QLQ-PR25 - European Organisation for Research and Treatment of Cancer QOL Questionnaire-Prostate Module; EORTC QLQ-C30 - European Organisation for Research and Treatment of Cancer (EORTC) core QOLquestionnaire